Therapeutic equivalence of fixed combination of indapamide with perindopril (Perindopril plus) in geriatric patients

Purpose. To study the therapeutic equivalence of the generic fixed combination of indapamide with perindopril (Perindopril plus, Severnaya Zvezda, Russia) in relation to the original drug in geriatric patients with hypertension (GB) and chronic heart failure (CHF). Material and methods. A study was conducted in 105 patients with GB and CHF (68.6 % of men with average age 80.3 ± 0.7 years), which evaluated the antihypertensive effect, the ability to correct heart failure, the presence of organ protection, the safety of both drugs. Results and discussion. When using a generic fixed combination, the achievement of the target value of office blood pressure was observed after a month of observation in all cases with stable maintenance by 6 months of the study; significant (p < 0.05) decrease in the level of home monitoring of systolic blood pressure (SBP) / diastolic blood pressure (DBP), after a month of research, by 26.1 % / 28.0 %, 6 months – by 26.8 % / 30.1 %; a significant (p < 0.05) decrease in the average daily SBP / DBP after a month of observation by 28.1 % / 28.6 % (after 6 months by 29.7 % / 29.5 %), the average daily – after a month of observation by 27.2 % / 28.2 % (after 6 months by 28.4 % / 31.7 %), average nightly – after a month of observation by 22.4 % / 24.1 % (after 6 months by 24.3 % / 27.1 %); a reliable (p < 0.05) decrease after a month of monitoring the average daily pulse pressure by 27.9 % (average daily pulse pressure by 25.8 %, average nightly pulse pressure by 20.1 %), after 6 months by 30.4 %, 23.5 %, 20.3 % respectively; a significant (p < 0.05) decrease in the carotid femoral pulse wave propagation velocity after a month by 17.9 %, after 6 months – by 26.8 %; after 6 months of observation, a reliable (p < 0.05) decrease in the final systolic volume of the left ventricle (LV) by 10.6 %, the final diastolic volume of the LV – by 7.5 %, the LV myocardial mass index – by 11.5 %, significant (p < 0.05) increase in LV ejection fraction by 2.9 %; significant (p < 0.05) decrease in FC of CHF by 20.7 % by the end of the study. According to the degree of change in these indicators, a generic fixed combination was comparable to the original drug. No side effects were observed in the comparison groups requiring discontinuation of treatment. Conclusions. The generic fixed combination of indapamide with perindopril (Perindopril plus, Severnaya Zvezda, Russia) has therapeutic equivalence with respect to the original drug.

1. Federal Law 61-FZ, dated 12 Apr. 2010, «On the circulation of drugs». Available on: http://www.consultant.ru/document/cons_doc_LAW_99350/.

2. Clinical Pharmacology / Edited by V. G. Kukes, D. A. Sychev. Textbook. 6th edition, revised and supplemented. – M.: GЕOTAR-Media, 2018; 1024 р.

3. United Nations. Agеing. Available on: https://www.un-.org/ru/sections/issues-depth/ageing/index.html

4. World Health Organization. Cardiovascular diseases. Available on: https://www.who.int/ru/news-room/factsheets/detail/cardiovascular-diseases-(cvds)

5. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018; 39 (33): 3021–3104. DOI: 10.1093/eurheartj/ehy339..

6. Doshchitsin V. L. Guide to рractical еlectrocardiography. – M.: MEDpress-Inform, 2015; 416 р.

7. Makarov L. M., Komolyatova V. N., Kupriyanova O. O., Pervova E. V., Ryabykina G. V., Sobolev A. V. et al. National russian guidelines on application of the methods of holter monitoring in clinical practice. Russian Journal of Cardiology. 2014; 2 (106): 6–71.

8. Parati G., Stergiou G., O’Brien E., Asmar R., Beilin L., Bilo G. et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. Journal of Hypertension. 2014; 32 (7): 1359–1366. DOI: 10.1097/HJH.0000000000000221.

9. Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015; 28 (1): 1–39. DOI: 10.1016/j.echo.2014.10.003.

10. Galderisi M., Cosyns B., Edvardsen T., Cardim N., Delgado V., Di Salvo G. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging. 2017; 18 (12): 1301–1310. DOI: 10.1093/ehjci/jex244.

11. Mareev V. Yu., Fomin I. V., Ageev F. T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A. A. et al. Russian Heart Failure Society, Russian Society of Cardiology, Russian Scientific Medical Society of Internal Medicine. Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Cardiology. 2018; 58 (S 6): 3–164.

12. Order of the Ministry of Health of the Russian Federation № 380, dated 25 Dec. 1997, «On the state and measures to improve laboratory support for the diagnosis and treatment of patients in healthcare facilities of the Russian Federation». Available on: http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=-EXP&n=430676#022793999513808116.

13. Chazova I. E., Zhernakova Yu.V. on behalf of experts. Clinical recommendations. Diagnosis and treatment of arterial hypertension. Systemic hypertension. 2019; 16 (1): 6–31.

14. Kochetkov A. I., Ostroumova O. D. The clinical implication of the target organ protective properties of antihypertensive drugs in new guidelines for the management of arterial hypertension: the benefit of calcium channel blockers and diuretics. Consilium Medicum. 2019; 21 (5): 11–18.

15. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundamental & Clinical Pharmacology. 2005; 19 (6): 637–645. DOI: 10.1111/j.1472–8206.2005.00377.x.

16. Mironneau J. Indapamide-induced inhibition of calcium movement in smooth muscles. American Journal of Medicine. 1988; 84 (1B): 10–14. DOI: 10.1016/0002–9343(88)90806–6.

17. Laurent S., Boutouyrie P. Vascular Mechanism Collaboration. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome. Hypertension. 2014; (4): 709–716. DOI: 10.1161/HYPERTENSIONAHA.114.03282.

18. Ong K. T., Delerme S., Pannier B., Safar M. E., Benetos A., Laurent S., Boutouyrie P. Aortic stiffness is reduced beyond blood pressure lowering by short-term and longterm antihypertensive treatment: a meta-analysis of individual data in 294 patients. Journal of Hypertension. 2011; 29 (6): 1034–1042. DOI: 10.1097/HJH.0b013e328346a583.

19. Shahin Y., Khan J. A., Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012; 221: 18–33. DOI: 10.1016/j.atherosclerosis.2011.12.005.

20. License No. 00003-LS, dated 23 Apr. 2019, for the production of medicines in accordance with the «Rules for the Organization of Production and Quality Control of Medicines (GMP)», approved by order of the Ministry of Industry and Trade of the Russian Federation, dated 14 June 2013 No. 916. Available on: https://ns03.ru/o-kompanii/litsenzii.php.